Cargando…
Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review
BACKGROUND: Drug-resistant tuberculosis (DR-TB) is considered to be a public health threat and is difficult to cure, requiring a lengthy treatment with potent, potentially toxic drugs. The novel antimicrobial agent bedaquiline has shown promising results for patients with DR-TB, improving the rate o...
Autores principales: | Mallick, Jahan Saeed, Nair, Parvati, Abbew, Elizabeth Tabitha, Van Deun, Armand, Decroo, Tom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963286/ https://www.ncbi.nlm.nih.gov/pubmed/35356403 http://dx.doi.org/10.1093/jacamr/dlac029 |
Ejemplares similares
-
Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis
por: Decroo, Tom, et al.
Publicado: (2022) -
Acquired Resistance of Mycobacterium tuberculosis to Bedaquiline
por: Andries, Koen, et al.
Publicado: (2014) -
Should treatment of low-level rifampicin mono-resistant tuberculosis be different?
por: Van Deun, Armand, et al.
Publicado: (2021) -
Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation
por: Starshinova, Anna, et al.
Publicado: (2022) -
Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan
por: Nair, P., et al.
Publicado: (2022)